At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 452 enrolled
Drug / intervention
Brincidofovir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
In Brief
A Phase 3 clinical trial evaluating Brincidofovir and Placebo for CMV. Completed, enrolled 452 participants across 43 sites in 3 countries.
Detailed Summary
This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive but negative for CMV viremia before starting treatment with BCV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCMV
CountriesBelgium, Canada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartAug 2013
Primary CompletionDec 2015
Study CompletionJan 2016
TodayJul 2026
First PostedJan 16, 2013
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.5 years ago
Interventions
Brincidofovirdrug
Placeboother